Jinkai Shengke (301509.SZ) reports a 171.46% year-on-year increase in net profit for 2025, proposing a dividend of 9 yuan per 10 shares.

According to the annual report released by Jinkai Bio-Pharmaceutical Technology (301509.SZ) on April 25th, the company achieved a total operating revenue of 639 million yuan in 2025, representing a year-on-year increase of 28.64%; net profit attributable to shareholders reached 105 million yuan, up 171.46% year-on-year; non-recurring net profit attributable to shareholders amounted to 82.3745 million yuan, surging 374.44% year-on-year. The company proposes a cash dividend of 9 yuan for every 10 shares to all shareholders.

Gelonghui FinanceApr 25 13:43

Jinkai Biotechnology: Summary of the 2025 Annual Report

SZSIApr 25 00:00 · Announcements

Jinkai Biotechnology: First Quarter Report for 2026

SZSIApr 25 00:00 · Announcements

Jinkai Biotechnology: 2025 Annual Report

SZSIApr 25 00:00 · Announcements

Jinkai Shengke (301509.SZ) announced its first-quarter performance, with a net profit attributable to shareholders of 16.6435 million yuan, representing a decrease of 64.90%.

Jinkai Shengke (301509.SZ) released its first-quarter report for 2026. The company's operating revenue amounted to 148 million yuan, representing a year-on-year decrease of 16.01%. The net profit attributable to shareholders of the listed company was 16.6435 million yuan, marking a year-on-year decline of 64.90%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 13.7758 million yuan, reflecting a year-on-year drop of 67.63%. The basic earnings per share were 0.14 yuan.

Zhitong FinanceApr 24 16:23

Express News | The innovative drug sector demonstrated strong performance, with Lianhuan Pharmaceuticals hitting the daily trading limit.

BreakingsMar 27 09:42